Immunostaining showed a significant increase in CD8+ cells in the TME for mice treated with PU-WS13 compared to untreated mice (1.95% ± 0.76% vs. 0.37% ± 0.20% of nucleated cells in the tumor, p = 0.0303) (Figure 4C). This evidence concerns the gene CD8A and neoplasm.